AstraZeneca, maker of one of the covid-19 vaccines available in Brazil, is focused on creating a cocktail of antibodies, also known as AZD7442, or Evusheld. This Thursday (14), the European Medicines Agency (EMA) began analyzing this cocktail to see if it will be authorized throughout the European Union.
The company has already performed tests that have shown that this combination of antibodies reduces severe symptoms and deaths from covid-19. The drug consists of monoclonal antibodies, which recognize a specific molecule of a virus or bacteria. In practice it is a synthetic version of natural antibodies. The cocktail should be given to people who have already been infected to alleviate immune system deficiencies.
According to the European Medicines Agency itself, the decision to analyze the AstraZeneca cocktail comes from “preliminary results of clinical studies, which suggest that the drug may help protect against disease”. But the process is not as fast as it sounds, and it can take months before possible authorization.
Want to catch up on the best tech news of the day? Access and subscribe to our new youtube channel, Canaltech News. Everyday a summary of the main news from the tech world for you!
According to AstraZeneca, Evusheld produced a satisfactory reduction in severe cases or deaths, something that was observed in a study of 903 people.
Did you like this article?
Subscribe your email on Canaltech to receive daily updates with the latest news from the world of technology.